A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Recruiting now Phase 3 NCT07216703
Run by Merck Sharp & Dohme LLC · for 18 and older · Women
What this study is about
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Who can join (things the study team will check)
The main inclusion criteria include but are not limited to the following: * Has a histologically confirmed diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of cervix * Has persistent, recurrent, or newly diagnosed metastatic (International Federation of Gynecology and Obstetrics \[FIGO\]-2028 Stage IVB) cervical cancer that is not amenable to curative treatment (surgery and/or radiation) * If infected with human immunodeficiency virus (HIV), has well controlled HIV on antiretroviral therapy * If positive for hepatitis B surface antigen, has received hepatitis B virus (HBV) antiviral therapy and has undetectable HBV viral load * If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load * Has an Eastern Cooperative Oncology Group performance status of 0 or 1 * Has tumor programmed cell death ligand 1 expression of combined positive score ≥1 The main exclusion criteria include but are not limited to the following: * Has HIV infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe …
Where this trial is running
- Mount Sinai Comprehensive Cancer Center ( Site 6000), Miami Beach, Florida, United States
- Florida Cancer Specialists - East ( Site 7000), West Palm Beach, Florida, United States
- Winship Cancer Institute of Emory University ( Site 5005), Atlanta, Georgia, United States
- Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005), Savannah, Georgia, United States
- TRIALS 365 ( Site 6008), Shreveport, Louisiana, United States
- Minnesota Oncology Hematology, PA ( Site 8003), Edina, Minnesota, United States
- Women's Cancer Center of Nevada ( Site 6011), Las Vegas, Nevada, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009), New York, New York, United States
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001), Tulsa, Oklahoma, United States
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007), Eugene, Oregon, United States
- Women & Infants Hospital ( Site 6003), Providence, Rhode Island, United States
- University of Tennessee Medical Center ( Site 6012), Knoxville, Tennessee, United States
+ 126 more sites.
Who to contact
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07216703.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.